Consortium québécois sur la découverte du médicament (CQDM) becomes shareholder in Mesentech
CQDM in conjunction with a pharmaceutical company partner invested $1.55M in Mesentech. Mesentech intends to advance MES-1007 through preclinical toxicology in order to validate how a bone-targeting technology can remedy peripheral organ toxicity while enhancing pharmacological efficacy.